Skip to main content

Peer Review reports

From: Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients

Original Submission
28 Feb 2020 Submitted Original manuscript
1 Jun 2020 Reviewed Reviewer Report
8 Jun 2020 Reviewed Reviewer Report - Efstathios Pavlidis
23 Jun 2020 Reviewed Reviewer Report
23 Jul 2020 Author responded Author comments - Luciene Schluckebier
Resubmission - Version 2
23 Jul 2020 Submitted Manuscript version 2
27 Jul 2020 Author responded Author comments - Luciene Schluckebier
Resubmission - Version 3
27 Jul 2020 Submitted Manuscript version 3
Publishing
30 Jul 2020 Editorially accepted
14 Sep 2020 Article published 10.1186/s12885-020-07240-2

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us